A Phase Ib/Ⅱ Clinical Trial of LBL-024 Combined With Paclitaxel in Patients With Platinum-resistant Ovarian Cancer
Conditions
Ovarian Cancer
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing Municipality, China
Beijing Obstetrics and Gynecology Hospital Capital Medical University, Beijing, Beijing Municipality, China
Fujian Cancer Hospital, Fuzhou, Fujian, China
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
AnYang Tumor Hospital, Anyang, Henan, China
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
The First Hospital of China Medical University, Shenyang, Liaoning, China
Shandong Cancer Hospital, Jinan, Shandong, China
Tianjin Medical University Cancer Institute &Hospital, Tianjin, Tianjin Municipality, China
Yunnan Cancer Hospital, Kunming, Yunnan, China
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Study leads
lingying wu
Principal Investigator
Cancer Institute and Hospital, Chinese Academy of Medical Sciences